Skip to main content

Advertisement

SpringerLink
Log in

THSD7A expression: a novel immunohistochemical determinant in predicting overall survival of metastatic renal cell carcinoma treated with targeted therapy

  • Original Article
  • Published:
Irish Journal of Medical Science (1971 -) Aims and scope Submit manuscript

Abstract

Background

The association of thrombospondin type 1 domain-containing 7A (THSD7A) expression, a novel angiogenesis-related marker, with survival outcomes of tumors including renal cell carcinoma (RCC) remains to be clarified. Therefore, we investigated the impact of THSD7A on outcomes of metastatic RCC (mRCC) patients treated with targeted therapy.

Methods

A total of 86 mRCC patients were included. The expression of THSD7A in nephrectomy material of the patients was assessed by immunohistochemistry and expression patterns were categorized into two groups: negative (no staining) and positive. Univariable and multivariable Cox regression models evaluated the impact of THSD7A expression on progression free survival (PFS) and overall survival (OS) of the patients.

Results

THSD7A expression was determined in 77.9% of the patients. Kaplan–Meier analyses showed that while the patients with THSD7A expression had significantly inferior OS times than those with negative THSD7A expression (19.9 months vs. 52.2 months, P = 0.024, respectively), there was no association between THSD7A expression and PFS. The univariate analyses demonstrated that the significant variables in predicting OS were presence of bone metastasis (P = 0.030), THSD7A expression (P = 0.028), and International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) scoring system (P < 0.001). However, applying multivariate analyses, the independent variables in predicting OS were THSD7A expression (HR: 2.639, P = 0.037) and IMDC scoring system (P < 0.001).

Conclusion

We revealed that THSD7A expression was associated with OS of mRCC patients treated with targeted therapy. There might be an important link between THSD7A expression and resistance to targeted therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Availability of data and material

Upon request.

Data availability statement

Research data are not shared.

References

  1. Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30. https://doi.org/10.3322/caac.21332

    Article  PubMed  Google Scholar 

  2. Heng DY, Xie W, Regan MM et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27:5794–5799. https://doi.org/10.1200/jco.2008.21.4809

    Article  CAS  PubMed  Google Scholar 

  3. Motzer RJ, Jonasch E, Michaelson MD et al (2019) NCCN guidelines insights: kidney cancer, Version 2.2020. J Natl Compr Canc Netw 17:1278–1285. https://doi.org/10.6004/jnccn.2019.0054

    Article  CAS  PubMed  Google Scholar 

  4. Sheets SSF (2015) Kidney and renal pelvis cancer. National Cancer Institue

  5. Linehan WM (2003) Molecular targeting of VHL gene pathway in clear cell kidney cancer. J Urol 170:593–594. https://doi.org/10.1097/01.ju.0000077210.05543.ae

    Article  PubMed  Google Scholar 

  6. Gödel M, Grahammer F, Huber TB (2015) Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 372:1073. https://doi.org/10.1056/NEJMc1500130

    Article  PubMed  Google Scholar 

  7. Hoxha E, Beck LH Jr, Wiech T et al (2017) An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7A-specific antibodies in membranous nephropathy. J Am Soc Nephrol 28:520–531. https://doi.org/10.1681/asn.2016010050

    Article  CAS  PubMed  Google Scholar 

  8. Stahl PR, Hoxha E, Wiech T et al (2017) THSD7A expression in human cancer. Genes Chromosomes Cancer 56:314–327. https://doi.org/10.1002/gcc.22440

    Article  CAS  PubMed  Google Scholar 

  9. Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655–663. https://doi.org/10.1097/00000478-198210000-00007

    Article  CAS  PubMed  Google Scholar 

  10. Paner GP, Amin MB, Alvarado-Cabrero I et al (2010) A novel tumor grading scheme for chromophobe renal cell carcinoma: prognostic utility and comparison with Fuhrman nuclear grade. Am J Surg Pathol 34:1233–1240. https://doi.org/10.1097/PAS.0b013e3181e96f2a

    Article  PubMed  Google Scholar 

  11. Sonpavde G, Choueiri TK (2012) Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma. Br J Cancer 107:1009–1016. https://doi.org/10.1038/bjc.2012.399

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Tomas NM, Beck LH Jr, Meyer-Schwesinger C et al (2014) Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 371:2277–2287. https://doi.org/10.1056/NEJMoa1409354

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Kuo MW, Wang CH, Wu HC et al (2011) Soluble THSD7A is an N-glycoprotein that promotes endothelial cell migration and tube formation in angiogenesis. PLoS One 6:e29000. https://doi.org/10.1371/journal.pone.0029000

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Gerhardt H, Golding M, Fruttiger M et al (2003) VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 161:1163–1177. https://doi.org/10.1083/jcb.200302047

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Benest AV, Harper SJ, Herttuala SY et al (2008) VEGF-C induced angiogenesis preferentially occurs at a distance from lymphangiogenesis. Cardiovasc Res 78:315–323. https://doi.org/10.1093/cvr/cvm094

    Article  CAS  PubMed  Google Scholar 

  16. Fletcher DA, Mullins RD (2010) Cell mechanics and the cytoskeleton. Nature 463:485–492. https://doi.org/10.1038/nature08908

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Peng X, Guan JL (2011) Focal adhesion kinase: from in vitro studies to functional analyses in vivo. Curr Protein Pept Sci 12:52–67. https://doi.org/10.2174/138920311795659452

    Article  CAS  PubMed  Google Scholar 

  18. Owens LV, Xu L, Craven RJ et al (1995) Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res 55:2752–2755

    CAS  PubMed  Google Scholar 

  19. Tremblay L, Hauck W, Aprikian AG et al (1996) Focal adhesion kinase (pp125FAK) expression, activation and association with paxillin and p50CSK in human metastatic prostate carcinoma. Int J Cancer 68:164–171. https://doi.org/10.1002/(sici)1097-0215(19961009)68:2%3c169::aid-ijc4%3e3.0.co;2-w

    Article  CAS  PubMed  Google Scholar 

  20. Kahana O, Micksche M, Witz IP et al (2002) The focal adhesion kinase (P125FAK) is constitutively active in human malignant melanoma. Oncogene 21:3969–3977. https://doi.org/10.1038/sj.onc.1205472

    Article  CAS  PubMed  Google Scholar 

  21. Cance WG, Golubovskaya VM (2008) Focal adhesion kinase versus p53: apoptosis or survival? Sci Signal 1:pe22. https://doi.org/10.1126/stke.120pe22

  22. Lechertier T, Hodivala-Dilke K (2012) Focal adhesion kinase and tumour angiogenesis. J Pathol 226:404–412. https://doi.org/10.1002/path.3018

    Article  CAS  PubMed  Google Scholar 

  23. Cary LA, Chang JF, Guan JL (1996) Stimulation of cell migration by overexpression of focal adhesion kinase and its association with Src and Fyn. J Cell Sci 109(Pt 7):1787–1794

    Article  CAS  Google Scholar 

  24. Mitra SK, Schlaepfer DD (2006) Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 18:516–523. https://doi.org/10.1016/j.ceb.2006.08.011

    Article  CAS  PubMed  Google Scholar 

  25. Béraud C, Dormoy V, Danilin S et al (2015) Targeting FAK scaffold functions inhibits human renal cell carcinoma growth. Int J Cancer 137:1549–1559. https://doi.org/10.1002/ijc.29522

    Article  CAS  PubMed  Google Scholar 

  26. Cao Y (2007) Angiogenesis modulates adipogenesis and obesity. J Clin Invest 117:2362–2368. https://doi.org/10.1172/jci32239

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Nizamuddin S, Govindaraj P, Saxena S et al (2015) A novel gene THSD7A is associated with obesity. Int J Obes (Lond) 39:1662–1665. https://doi.org/10.1038/ijo.2015.144

    Article  CAS  Google Scholar 

Download references

Funding

This work is supported by the Department of Scientific Research Projects Coordination Unit of Hacettepe University (project no: 18449).

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Bolu Abant Izzet Baysal University, 14030, Bolu, Turkey

    Oktay Halit Aktepe

  2. Department of Pathology, Faculty of Medicine, Hacettepe University, Ankara, Turkey

    Fatma Gundogdu & Kemal Kosemehmetoglu

  3. Department of Nephrology, Faculty of Medicine, Gazi University, Ankara, Turkey

    Haci Hasan Yeter

  4. Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey

    Sercan Aksoy, Deniz Can Guven, Neyran Kertmen & Suayib Yalcin

  5. Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey

    Taha Koray Sahin

  6. Department of Preventive Oncology, Hacettepe University Cancer Institute, Ankara, Turkey

    Deniz Yuce, Omer Dizdar & Mustafa Erman

Authors
  1. Oktay Halit Aktepe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fatma Gundogdu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kemal Kosemehmetoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Haci Hasan Yeter
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sercan Aksoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Deniz Can Guven
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Taha Koray Sahin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Deniz Yuce
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Neyran Kertmen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Omer Dizdar
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Suayib Yalcin
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Mustafa Erman
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

OHA, FG, KK, and ME designed the research; FG, KK, SA, TKS, OD, NK, and SY conducted the research; OHA, HHY, DY, and OD analyzed the data; OHA, FG, KK, HHY, SA, and ME wrote the paper; OHA had primary responsibility for final content. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Oktay Halit Aktepe.

Ethics declarations

Consent to participate

Informed consent was obtained from all individual participants or their relatives included in the study.

Consent for publication

Patients or their relatives signed informed consent regarding publishing their data and photograph.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aktepe, O.H., Gundogdu, F., Kosemehmetoglu, K. et al. THSD7A expression: a novel immunohistochemical determinant in predicting overall survival of metastatic renal cell carcinoma treated with targeted therapy. Ir J Med Sci 191, 1561–1567 (2022). https://doi.org/10.1007/s11845-021-02759-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11845-021-02759-0

Keywords

Search

Navigation